Literature DB >> 33118249

Evidence supporting wound care end points relevant to clinical practice and patients' lives. Part 3: The Patient Survey.

Lisa J Gould1,2, Jing Liu3, Rou Wan3, Marissa J Carter4, Margaret Peggy Dotson5,6, Vickie R Driver7.   

Abstract

The 2006 U.S. Food and Drug Administration Guidance for Industry emphasizes wound closure as the primary outcome for clinical trials in wound healing. Wound care professionals understand that complete wound healing is not always achievable when evaluating new treatments. FDA, Association for the Advancement of Wound Care, and Wound Healing Society are working collaboratively to identify scientifically achievable, clinically relevant, and patient-centered endpoints with sufficient support to serve as primary outcomes for clinical trials. The Opinion Survey from People with Wounds presented here addresses an important but understudied issue: the gap between clinician, healthcare insurance companies, government agencies, and patient perspectives regarding clinically meaningful and scientifically achievable primary endpoints for wound care. The survey, adapted from the clinician survey with adjustment for health literacy, was pilot tested and revised based on a limited number of patients in a single clinic. After central IRB approval, the on-line survey was administered in English and Spanish and submitted anonymously to a server with the cooperation of multiple wound clinics and societies. Four hundred and thirty-eight patients and caregivers from across the United States responded over a 10-month period. Based on this survey, the most valuable clinical endpoints were reduced infection, recurrence, and amputation. The most valuable quality of life outcomes were increased independence, reduced social isolation, and pain. The top five endpoints in terms of usefulness for measuring clinical trial success were time to heal, wound size, infection, recurrence, and pain. Narrative responses from wound patients emphasized the inability to perform activities of daily living and pain as major factors that impacted their daily lives. Engagement of patients in clinical trials and evaluation of potential treatments is critical to improving wound care. This survey provides insight into the needs of patients with wounds and provides a roadmap for structuring future clinical trials to better meet those needs.
© 2020 The Wound Healing Society.

Entities:  

Year:  2020        PMID: 33118249     DOI: 10.1111/wrr.12872

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  4 in total

1.  Accelerated Wound Healing in Minipigs by On-Site Production and Delivery of CXCL12 by Transformed Lactic Acid Bacteria.

Authors:  Emelie Öhnstedt; Hava Lofton Tomenius; Peter Frank; Stefan Roos; Evelina Vågesjö; Mia Phillipson
Journal:  Pharmaceutics       Date:  2022-01-19       Impact factor: 6.321

2.  Chronic wounds: Treatment consensus.

Authors:  Elof Eriksson; Paul Y Liu; Gregory S Schultz; Manuela M Martins-Green; Rica Tanaka; Dot Weir; Lisa J Gould; David G Armstrong; Gary W Gibbons; Randy Wolcott; Oluyinka O Olutoye; Robert S Kirsner; Geoffrey C Gurtner
Journal:  Wound Repair Regen       Date:  2022-02-07       Impact factor: 3.401

3.  Ankle brachial indices and anaerobes: is peripheral arterial disease associated with anaerobic bacteria in diabetic foot ulcers?

Authors:  J Z Alex Cheong; Jessica M Irvine; Shane Roesemann; Anna Nora; Courtney E Morgan; Christopher Daniele; Lindsay R Kalan; Meghan B Brennan
Journal:  Ther Adv Endocrinol Metab       Date:  2022-08-23       Impact factor: 4.435

4.  International study to develop the WOUND-Q patient-reported outcome measure for all types of chronic wounds.

Authors:  Anne F Klassen; Emiel L W G van Haren; Tert C van Alphen; Stefan Cano; Karen M Cross; Anne-Margreet van Dishoeck; Kenneth L Fan; Maarten Michael Hoogbergen; Dennis Orgill; Lotte Poulsen; Jens Ahm Sørensen; Lee Squitieri; Elena Tsangaris; Dalibor Vasilic; Andrea L Pusic
Journal:  Int Wound J       Date:  2021-03-10       Impact factor: 3.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.